Novel complement C1 inhibitor BSF468248 does not improve brain damage after cortical vein occlusion.
BSF468248 is a novel potent complement C1 inhibitor. To determine whether BSF468248 is effective against focal cerebral ischemia, we evaluated the change of cerebral blood flow (CBF) and infarction volume using a photochemically-induced cortical vein occlusion model in rats in blind studies. In 22 Wistar rats, two adjacent cortical veins were occluded by photochemical thrombosis and fiberoptic illumination under controlled anesthesia and ventilation. Just after the occlusion, BSF468248 or physiological saline was administrated. In the low-dose study, a treatment group (n = 7) was administered BSF468248 1 mg/kg bolus and 1 mg/kg continuously for 30 min. The same volume of saline was given to a vehicle group (n = 5). In the high-dose study, a treatment group (n = 5) was administrated BSF468248 1 mg/kg bolus and 12 mg/kg continuously for 180 min. The same volume of saline was given to a vehicle group (n = 5). During the experiment, regional cerebral blood flow (rCBF) was measured in both the low-dose study (120 min) and the high-dose study (180 min). Seven days after the experiment, the animals were killed in order to evaluate the infarct volume. The rCBF at the end of the experiment showed a similar decrease in both the low-dose study (at 120 min: treatment group: 66.5 +/- 10.2%; vehicle group: 69.3 +/- 10.2%) and the high-dose study (at 180 min: treatment group: 62.1 +/- 7.5%; vehicle group: 65.1 +/- 12.3%), with no significant differences (t-test). The infarct volume also showed no significant difference in either group of the low-dose study (treatment group: 3.46 +/- 0.84 mm3; vehicle group: 3.56 +/- 1.40 mm3) or the high-dose study (treatment group: 2.27 +/- 0.43 mm3; vehicle group: 1.76 +/- 0.31 mm3). Our study found that BSF468248 is not effective in improving the rCBF and the infarct volume following focal cerebral ischemia.
Kaido
T
T
Institute for Neurosurgical Pathophysiology, Johannes Gutenberg-University Mainz, Mainz, Germany. kaido@nmu-gw.naramed-u.ac.jp
Heimann
A
A
Kempski
O
O
D000818:Animals; D001930:Brain Injuries / Q000188:drug therapy*; D002540:Cerebral Cortex / Q000098:blood supply* / Q000187:drug effects / Q000503:physiopathology; D002544:Cerebral Infarction / Q000503:physiopathology*; D002550:Cerebral Veins / Q000187:drug effects / Q000503:physiopathology; D002560:Cerebrovascular Circulation / Q000187:drug effects; D003174:Complement C1 Inactivator Proteins / Q000008:administration & dosage / Q000494:pharmacology*; D004195:Disease Models, Animal; D007262:Infusions, Intravenous; D020767:Intracranial Thrombosis / Q000150:complications* / Q000503:physiopathology; D008297:Male; D009842:Oligopeptides / Q000008:administration & dosage / Q000494:pharmacology*; D010777:Photochemistry; D051381:Rats; D017207:Rats, Sprague-Dawley; D017208:Rats, Wistar; D012039:Regional Blood Flow / Q000187:drug effects; D016896:Treatment Outcome
C487136:BSF 468248; D003174:Complement C1 Inactivator Proteins; D009842:Oligopeptides